Nieuws

dec
3

Indicative text 11th IMI Call published

IMI (Innovative Medicines Initiative) has published an indicative text of the 11th Call for proposals, which is scheduled for launch later in December this year. The 11th Call comprises eight topics:
• Applied public-private research enabling osteoarthritis clinical headway;
• European platform for proof of concept for prevention in Alzheimer’s Disease;
• Blood-based biomarker assays for personalised tumour therapy: value of latest circulating biomarkers;
• Zoonoses anticipation and preparedness initiative;
• Generation of research tools to translate genomic discoveries into drug discovery projects;
• Ecorisk prediction;

Under the Theme New Drugs for Bad Bugs (ND4BB):
• ND4BB Topic 6: Epidemiology research and development of novel systemic antibacterial molecules against healthcare-associated infections due to Gram-negative pathogens;
• ND4BB Topic 7: Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-CF bronchiectasis (BE).

The total available financial contribution from the IMI JU to participants eligible for funding will be up to € 175,600,000. The indicative EFPIA 'in kind' contribution will be € 200,460,000. The  duration of a project will probably be between 4 and 5 years.
The 10th Call is currently open and closes January 28, 2014.

The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in Europe that will boost innovation in healthcare. Acting as a neutral third party in creating innovative partnerships, IMI aims to build a more collaborative ecosystem for pharmaceutical research and development (R&D). IMI will provide socio-economic benefits to European citizens, increase Europe's competitiveness globally and establish Europe as the most attractive place for pharmaceutical R&D.

Terug naar overzicht